Dynatronics (NASDAQ:DYNT) Stock Rating Upgraded by Zacks Investment Research

Dynatronics (NASDAQ:DYNT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports.

According to Zacks, “DYNATRONICS CORP. is involved in the design, manufacture and sale of medical devices for therapeutic use by medical practitioners. “

Other research analysts have also issued reports about the company. Roth Capital reissued a “buy” rating on shares of Dynatronics in a research report on Thursday, February 17th. StockNews.com began coverage on Dynatronics in a research note on Monday. They issued a “hold” rating for the company. Finally, TheStreet downgraded Dynatronics from a “c-” rating to a “d+” rating in a research note on Friday, February 11th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $2.13.

NASDAQ:DYNT traded up $0.01 during trading hours on Wednesday, hitting $0.73. 27,662 shares of the company were exchanged, compared to its average volume of 57,808. The company has a market cap of $13.14 million, a PE ratio of 8.13 and a beta of -0.06. The company has a quick ratio of 1.30, a current ratio of 2.38 and a debt-to-equity ratio of 0.12. Dynatronics has a one year low of $0.67 and a one year high of $1.79. The business’s fifty day moving average is $0.76.

Dynatronics (NASDAQ:DYNT – Get Rating) last posted its quarterly earnings data on Thursday, February 10th. The medical equipment provider reported ($0.09) earnings per share for the quarter. Dynatronics had a return on equity of 12.52% and a net margin of 4.50%. The business had revenue of $10.53 million during the quarter. During the same period in the previous year, the business posted ($0.06) earnings per share. On average, research analysts anticipate that Dynatronics will post -0.21 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its stake in Dynatronics by 11.3% during the 3rd quarter. Renaissance Technologies LLC now owns 801,165 shares of the medical equipment provider’s stock valued at $1,170,000 after purchasing an additional 81,600 shares during the last quarter. Millennium Management LLC bought a new position in shares of Dynatronics during the 3rd quarter worth approximately $120,000. Goldman Sachs Group Inc. bought a new position in shares of Dynatronics during the 3rd quarter worth approximately $56,000. Finally, Citadel Advisors LLC bought a new position in shares of Dynatronics during the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 9.95% of the company’s stock.

About Dynatronics (Get Rating)

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. Its orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products.

Further Reading